Mark Terry of BioSpace reports on Atomwise’s three new joint ventures.
Atomwise and Atropos Therapeutics form a joint venture to discover and develop anticancer agents using senescence assay and AI technologies.
Connor Hale at FierceBiotech writes about Atomwise’s new joint ventures with SEngine Precision Medicine and OncoStatyx.
Atomwise and OncoStatyx announce a joint venture to discover and develop small molecule compounds that inhibit KDM5B.
Joint venture brings together AI technology and living tumor organoids to develop novel personalized therapies for cancer patients SEATTLE, Wash., and SAN FRANCISCO, Calif. – SEngine Precision Medicine and Atomwise, Inc. today announced a joint venture to accelerate novel oncology drug discovery utilizing the unique platform technologies each company has validated through years of development. […]
Mel Yeates from DDNews reports on some of Atomwise’s recent partnerships with Eli Lilly and Enamine.